HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 113; no. 26; pp. E3735 - E3744 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
28.06.2016
|
Series | PNAS Plus |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer. |
---|---|
AbstractList | Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer. The plasticity of Polycomb repressive complex 2 (PRC2) in the context of tumorigenesis has remained a subject of contention. Here we demonstrate that the equilibrium between the oncogenic and tumor-suppressive activity of PRC2 in promoting breast cancer invasion is tightly regulated by hypoxia-inducible factor 1-α. PRC2 acts as a tumor-suppressor barrier to the hypoxia-driven invasion pathway, and the impaired PRC2 activity upon hypoxia promotes a chromatin switch at proinvasion matrix metalloproteinase gene loci. The study fundamentally changed our understanding of the role of PRC2 in breast cancer and also identified a previously unidentified function of enhancer of zeste 2 to complex with Forkhead box M1 to promote cancer invasion. Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes ( MMP s) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMP s. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog ( SUZ12 ) and embryonic ectoderm development ( EED ), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMP s and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer. |
Author | Mahara, Sylvia Tergaonkar, Vinay Chng, Wee Joo Yu, Qiang Lee, Puay Leng Feng, Min |
Author_xml | – sequence: 1 givenname: Sylvia surname: Mahara fullname: Mahara, Sylvia organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672 – sequence: 2 givenname: Puay Leng surname: Lee fullname: Lee, Puay Leng organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672 – sequence: 3 givenname: Min surname: Feng fullname: Feng, Min organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672 – sequence: 4 givenname: Vinay surname: Tergaonkar fullname: Tergaonkar, Vinay organization: SA Pathology, Adelaide, SA 5000, Australia – sequence: 5 givenname: Wee Joo surname: Chng fullname: Chng, Wee Joo organization: Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597 – sequence: 6 givenname: Qiang surname: Yu fullname: Yu, Qiang organization: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27303043$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uc1u1DAQtlAR3RbOnEA-ckl3bCdOfEFCq5auVAmE4Gw5zph1lbUX2yk_b8WL8Exk2ZYCEqeRZr6fmflOyFGIAQl5yuCMQSuWu2DyGZPAoVWMiQdkwUCxStYKjsgCgLdVV_P6mJzkfA0AqungETnmrQABtVgQd7m-WFc_vlNji78xxcdApzBgGj1maqibgt03zUjzZ1_shvpAywbpziQzxC_ezpMUR6TR0fNvG758-27F96A-ocmFWhMspsfkoTNjxie39ZR8uDh_v7qsrt68Xq9eXVW2Zk2pLLbOdW4-xyGX3M63KAEKhZSdHZRTQjQwoAQQqlVoOuh7aV1tZd-0VvXilLw86O6mfouDxVCSGfUu-a1JX3U0Xv89CX6jP8YbXSvBVaNmgRe3Ail-mjAXvfXZ4jiagHHKmnUALfBOsBn6_E-v3yZ3z50BzQFgU8w5odPWl18vnq39qBnofYh6H6K-D3HmLf_h3Un_n_HswLjOJab7TWTdgpSN-AlXR6nk |
CitedBy_id | crossref_primary_10_1172_jci_insight_157502 crossref_primary_10_1186_s40364_018_0122_2 crossref_primary_10_3389_fphar_2024_1416992 crossref_primary_10_1016_j_ajpath_2021_01_013 crossref_primary_10_1074_jbc_M117_810127 crossref_primary_10_1177_17588359241306026 crossref_primary_10_1093_lifemeta_loae017 crossref_primary_10_1111_jcmm_17450 crossref_primary_10_1111_cas_14840 crossref_primary_10_1038_s41418_024_01271_z crossref_primary_10_1186_s12885_022_10312_0 crossref_primary_10_1158_0008_5472_CAN_20_2612 crossref_primary_10_1038_s41418_021_00836_6 crossref_primary_10_4103_JCSR_JCSR_67_19 crossref_primary_10_1038_s41388_019_1123_9 crossref_primary_10_3390_ijms22063218 crossref_primary_10_1111_cas_14905 crossref_primary_10_3390_ijms241713596 crossref_primary_10_3389_fgene_2021_658241 crossref_primary_10_3389_fcell_2021_736935 crossref_primary_10_3390_life14121645 crossref_primary_10_3892_mmr_2017_8160 crossref_primary_10_3389_fphar_2022_1115608 crossref_primary_10_1073_pnas_2201376119 crossref_primary_10_1016_j_enceco_2025_03_005 crossref_primary_10_1016_j_celrep_2018_03_013 crossref_primary_10_1172_jci_insight_166860 crossref_primary_10_1038_s41598_018_36560_4 crossref_primary_10_1172_JCI161638 crossref_primary_10_1186_s13148_023_01593_8 crossref_primary_10_3390_cancers14092121 crossref_primary_10_1007_s10142_025_01563_8 crossref_primary_10_1038_s41374_018_0104_x crossref_primary_10_1089_genbio_2023_0020 crossref_primary_10_3389_fped_2018_00328 crossref_primary_10_1007_s11060_024_04736_w crossref_primary_10_1042_BSR20222230 crossref_primary_10_1007_s10555_020_09905_7 crossref_primary_10_1016_j_bbagrm_2019_01_002 crossref_primary_10_1016_j_bbcan_2023_188903 crossref_primary_10_1016_j_lfs_2021_120047 crossref_primary_10_1038_s41388_024_03119_9 crossref_primary_10_1124_mol_119_117432 crossref_primary_10_3390_ijms21249501 crossref_primary_10_1080_08977194_2023_2297693 crossref_primary_10_1186_s12943_023_01786_y crossref_primary_10_1016_j_diff_2021_08_001 crossref_primary_10_3390_ijms18061172 crossref_primary_10_1038_s41419_021_04461_6 crossref_primary_10_1016_j_biopha_2024_116624 crossref_primary_10_1002_cam4_70274 crossref_primary_10_1038_s41419_019_1935_0 crossref_primary_10_1038_s41594_019_0299_6 crossref_primary_10_1080_15384101_2016_1215699 crossref_primary_10_1038_s41388_020_01484_9 crossref_primary_10_1073_pnas_2019052118 crossref_primary_10_18632_oncotarget_20202 crossref_primary_10_1002_jcp_30992 crossref_primary_10_1016_j_semcancer_2021_03_025 crossref_primary_10_1016_j_canlet_2020_05_025 crossref_primary_10_3390_ijms24031963 crossref_primary_10_3892_ol_2019_10769 crossref_primary_10_1038_s41698_024_00691_x crossref_primary_10_1038_s41467_022_31764_9 crossref_primary_10_1042_BSR20180268 crossref_primary_10_1002_wrna_1750 crossref_primary_10_1038_s41416_025_02961_2 crossref_primary_10_1016_j_semcancer_2023_10_005 |
Cites_doi | 10.1002/mc.20413 10.2217/fon.13.92 10.1038/sj.emboj.7601369 10.4161/cc.8.12.8708 10.1158/1541-7786.MCR-10-0511 10.1074/jbc.272.31.19253 10.1126/science.1227604 10.1073/pnas.1933744100 10.1309/LMLIK0VIE3CJK0WD 10.18632/oncotarget.6612 10.1371/journal.pone.0005011 10.1101/gad.924501 10.1038/nature10983 10.1101/gad.181800.111 10.1038/nature11412 10.1073/pnas.0932692100 10.1016/j.molonc.2012.06.002 10.1158/0008-5472.CAN-11-3546 10.1016/j.ccell.2015.12.006 10.1038/nature10725 10.3892/ol_00000115 10.1101/gad.1524107 10.1158/0008-5472.CAN-10-4087 10.1038/nature11606 10.1038/nm.2651 10.1101/gad.1035902 10.1016/j.molcel.2005.02.015 10.1016/j.molcel.2013.08.028 10.1016/B978-0-12-407173-5.00004-2 10.1002/mc.22188 10.1016/j.biopha.2015.07.038 10.1038/nature06905 10.1038/ng.620 10.1073/pnas.191367098 10.1016/j.ccr.2013.04.008 10.1038/onc.2011.417 10.1016/j.ccr.2007.04.001 10.1002/jcb.21996 10.1073/pnas.1520032112 10.1074/jbc.M209114200 10.1038/ng.621 10.1182/blood-2012-08-450494 10.1172/JCI80325 10.1007/s10549-011-1345-1 10.1001/jama.2011.593 10.1074/jbc.M111.270843 10.1038/35021093 10.1038/onc.2008.333 10.1007/s10549-009-0572-1 10.1038/nm.3029 10.1016/j.ccr.2010.10.035 10.1073/pnas.1308953111 10.1016/j.molcel.2011.08.011 10.1371/journal.pone.0031761 10.1007/s10549-014-3089-1 10.1091/mbc.e07-04-0391 10.1101/gad.269522.115 10.1371/journal.pone.0017911 10.1093/emboj/cdg542 10.1074/jbc.M204733200 10.1101/gad.191163.112 |
ContentType | Journal Article |
Copyright | Volumes 1–89 and 106–113, copyright as a collective work only; author(s) retains copyright to individual articles |
Copyright_xml | – notice: Volumes 1–89 and 106–113, copyright as a collective work only; author(s) retains copyright to individual articles |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1073/pnas.1602079113 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
DocumentTitleAlternate | HIF1-α inhibits PRC2 to promote Ezh2/FoxM1 |
EISSN | 1091-6490 |
EndPage | E3744 |
ExternalDocumentID | PMC4932959 27303043 10_1073_pnas_1602079113 26470665 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -DZ -~X .55 0R~ 123 29P 2AX 2FS 2WC 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT AENEX AEUPB AEXZC AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM BKOMP CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 N9A N~3 O9- OK1 PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR W8F WH7 WOQ WOW X7M XSW Y6R YBH YKV YSK ZCA ~02 ~KM AAYXX AFOSN CITATION CGR CUY CVF DOOOF ECM EIF JSODD NPM RHF VQA YIF YIN 7X8 5PM |
ID | FETCH-LOGICAL-c415t-ce7ff8f020fe262c0919309e3668cd9f93350de6003979ea80bb6cf4c6b57c9b3 |
ISSN | 0027-8424 |
IngestDate | Thu Aug 21 18:04:57 EDT 2025 Fri Jul 11 08:42:37 EDT 2025 Wed Feb 19 02:39:58 EST 2025 Thu Apr 24 22:57:56 EDT 2025 Tue Jul 01 03:19:16 EDT 2025 Sun Aug 24 12:10:43 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 26 |
Keywords | hypoxia breast cancer PRC2 FOXM1 EZH2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c415t-ce7ff8f020fe262c0919309e3668cd9f93350de6003979ea80bb6cf4c6b57c9b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: S.M. and Q.Y. designed research; S.M., P.L.L., and M.F. performed research; V.T. contributed new reagents/analytic tools; S.M. and W.J.C. analyzed data; Q.Y. supervised the project; and S.M. and Q.Y. wrote the paper. Edited by Gregg L. Semenza, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved May 17, 2016 (received for review February 6, 2016) |
OpenAccessLink | https://www.pnas.org/content/pnas/113/26/E3735.full.pdf |
PMID | 27303043 |
PQID | 1800702831 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4932959 proquest_miscellaneous_1800702831 pubmed_primary_27303043 crossref_citationtrail_10_1073_pnas_1602079113 crossref_primary_10_1073_pnas_1602079113 jstor_primary_26470665 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-06-28 |
PublicationDateYYYYMMDD | 2016-06-28 |
PublicationDate_xml | – month: 06 year: 2016 text: 2016-06-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationSeriesTitle | PNAS Plus |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 2016 |
Publisher | National Academy of Sciences |
Publisher_xml | – name: National Academy of Sciences |
References | e_1_3_3_50_2 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_58_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_61_2 e_1_3_3_5_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_1_2 e_1_3_3_44_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_51_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_59_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_57_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_60_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 12052835 - J Biol Chem. 2002 Aug 16;277(33):29936-44 26517694 - J Clin Invest. 2015 Oct 26;125(12 ):4375-90 15780936 - Mol Cell. 2005 Mar 18;17(6):793-803 25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 17482131 - Cancer Cell. 2007 May;11(5):407-20 23529930 - Blood. 2013 May 30;121(22):4512-20 25043748 - Mol Carcinog. 2015 Oct;54(10 ):1172-80 24156323 - Future Oncol. 2013 Nov;9(11):1623-36 18806826 - Oncogene. 2008 Dec 11;27(58):7274-84 24055345 - Mol Cell. 2013 Oct 24;52(2):193-205 21383005 - Mol Cancer Res. 2011 Apr;9(4):418-29 12379645 - J Biol Chem. 2002 Dec 13;277(50):48403-9 23239736 - Science. 2012 Dec 14;338(6113):1465-9 26766588 - Cancer Cell. 2016 Jan 11;29(1):17-31 26637281 - Genes Dev. 2015 Dec 15;29(24):2547-62 12435631 - Genes Dev. 2002 Nov 15;16(22):2893-905 18432192 - Nature. 2008 Jun 5;453(7196):807-11 23768511 - Adv Cancer Res. 2013;118:97-398 20601954 - Nat Genet. 2010 Aug;42(8):665-7 26271144 - Biomed Pharmacother. 2015 Oct;75:218-25 22508723 - Genes Dev. 2012 Apr 15;26(8):751-5 17024177 - EMBO J. 2006 Oct 18;25(20):4784-94 23684459 - Cancer Cell. 2013 Jun 10;23 (6):839-52 24516139 - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103 20601953 - Nat Genet. 2010 Aug;42(8):722-6 22766277 - Mol Oncol. 2012 Oct;6(5):494-506 14532106 - EMBO J. 2003 Oct 15;22(20):5323-35 22966359 - Oncol Lett. 2010 Jul;1(4):657-662 21445301 - PLoS One. 2011 Mar 21;6(3):e17911 22237151 - Nat Med. 2012 Feb 06;18(2):298-301 26683709 - Oncotarget. 2016 Jan 26;7(4):4584-97 21558518 - JAMA. 2011 May 11;305(18):1873-81 21225456 - Breast Cancer Res Treat. 2011 Apr;126(3):803-10 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 23051747 - Nature. 2012 Dec 6;492(7427):108-12 18176935 - Mol Carcinog. 2008 Sep;47(9):701-6 11641274 - Genes Dev. 2001 Oct 15;15(20):2675-86 21884980 - Mol Cell. 2011 Sep 2;43(5):798-810 17437993 - Genes Dev. 2007 May 1;21(9):1050-63 22391448 - Genes Dev. 2012 Mar 1;26(5):439-44 26512116 - Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23 21979956 - J Biol Chem. 2011 Dec 2;286(48):41425-33 19813088 - Breast Cancer Res Treat. 2010 Jul;122(2):337-46 21927022 - Oncogene. 2012 May 3;31(18):2283-97 17898080 - Mol Biol Cell. 2007 Dec;18(12 ):4691-7 19340297 - PLoS One. 2009;4(4):e5011 9235919 - J Biol Chem. 1997 Aug 1;272(31):19253-60 12829800 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 23223005 - Nat Med. 2013 Jan;19(1):50-6 21215703 - Cancer Cell. 2011 Jan 18;19(1):86-100 22237106 - Nature. 2012 Jan 11;481(7380):157-63 23000897 - Nature. 2012 Oct 4;490(7418):61-70 22505648 - Cancer Res. 2012 Jun 15;72 (12 ):3091-104 22393369 - PLoS One. 2012;7(2):e31761 21507930 - Cancer Res. 2011 Jun 15;71(12 ):4292-302 10963602 - Nature. 2000 Aug 17;406(6797):747-52 19411834 - Cell Cycle. 2009 Jun 15;8(12 ):1966-7 19097132 - J Cell Biochem. 2009 Feb 1;106(2):247-56 22522925 - Nature. 2012 Apr 18;486(7403):346-52 |
References_xml | – ident: e_1_3_3_21_2 doi: 10.1002/mc.20413 – ident: e_1_3_3_28_2 doi: 10.2217/fon.13.92 – ident: e_1_3_3_35_2 doi: 10.1038/sj.emboj.7601369 – ident: e_1_3_3_45_2 doi: 10.4161/cc.8.12.8708 – ident: e_1_3_3_39_2 doi: 10.1158/1541-7786.MCR-10-0511 – ident: e_1_3_3_48_2 doi: 10.1074/jbc.272.31.19253 – ident: e_1_3_3_11_2 doi: 10.1126/science.1227604 – ident: e_1_3_3_23_2 doi: 10.1073/pnas.1933744100 – ident: e_1_3_3_5_2 doi: 10.1309/LMLIK0VIE3CJK0WD – ident: e_1_3_3_7_2 doi: 10.18632/oncotarget.6612 – ident: e_1_3_3_40_2 doi: 10.1371/journal.pone.0005011 – ident: e_1_3_3_49_2 doi: 10.1101/gad.924501 – ident: e_1_3_3_24_2 doi: 10.1038/nature10983 – ident: e_1_3_3_61_2 doi: 10.1101/gad.181800.111 – ident: e_1_3_3_4_2 doi: 10.1038/nature11412 – ident: e_1_3_3_3_2 doi: 10.1073/pnas.0932692100 – ident: e_1_3_3_19_2 doi: 10.1016/j.molonc.2012.06.002 – ident: e_1_3_3_41_2 doi: 10.1158/0008-5472.CAN-11-3546 – ident: e_1_3_3_18_2 doi: 10.1016/j.ccell.2015.12.006 – ident: e_1_3_3_59_2 doi: 10.1038/nature10725 – ident: e_1_3_3_38_2 doi: 10.3892/ol_00000115 – ident: e_1_3_3_31_2 doi: 10.1101/gad.1524107 – ident: e_1_3_3_56_2 doi: 10.1158/0008-5472.CAN-10-4087 – ident: e_1_3_3_46_2 doi: 10.1038/nature11606 – ident: e_1_3_3_58_2 doi: 10.1038/nm.2651 – ident: e_1_3_3_6_2 doi: 10.1101/gad.1035902 – ident: e_1_3_3_36_2 doi: 10.1016/j.molcel.2005.02.015 – ident: e_1_3_3_12_2 doi: 10.1016/j.molcel.2013.08.028 – ident: e_1_3_3_32_2 doi: 10.1016/B978-0-12-407173-5.00004-2 – ident: e_1_3_3_20_2 doi: 10.1002/mc.22188 – ident: e_1_3_3_27_2 doi: 10.1016/j.biopha.2015.07.038 – ident: e_1_3_3_51_2 doi: 10.1038/nature06905 – ident: e_1_3_3_15_2 doi: 10.1038/ng.620 – ident: e_1_3_3_2_2 doi: 10.1073/pnas.191367098 – ident: e_1_3_3_9_2 doi: 10.1016/j.ccr.2013.04.008 – ident: e_1_3_3_34_2 doi: 10.1038/onc.2011.417 – ident: e_1_3_3_37_2 doi: 10.1016/j.ccr.2007.04.001 – ident: e_1_3_3_26_2 doi: 10.1002/jcb.21996 – ident: e_1_3_3_30_2 doi: 10.1073/pnas.1520032112 – ident: e_1_3_3_53_2 doi: 10.1074/jbc.M209114200 – ident: e_1_3_3_14_2 doi: 10.1038/ng.621 – ident: e_1_3_3_10_2 doi: 10.1182/blood-2012-08-450494 – ident: e_1_3_3_54_2 doi: 10.1172/JCI80325 – ident: e_1_3_3_29_2 doi: 10.1007/s10549-011-1345-1 – ident: e_1_3_3_47_2 doi: 10.1001/jama.2011.593 – ident: e_1_3_3_57_2 doi: 10.1074/jbc.M111.270843 – ident: e_1_3_3_1_2 doi: 10.1038/35021093 – ident: e_1_3_3_42_2 doi: 10.1038/onc.2008.333 – ident: e_1_3_3_44_2 doi: 10.1007/s10549-009-0572-1 – ident: e_1_3_3_60_2 doi: 10.1038/nm.3029 – ident: e_1_3_3_25_2 doi: 10.1016/j.ccr.2010.10.035 – ident: e_1_3_3_13_2 doi: 10.1073/pnas.1308953111 – ident: e_1_3_3_8_2 doi: 10.1016/j.molcel.2011.08.011 – ident: e_1_3_3_55_2 doi: 10.1371/journal.pone.0031761 – ident: e_1_3_3_22_2 doi: 10.1007/s10549-014-3089-1 – ident: e_1_3_3_52_2 doi: 10.1091/mbc.e07-04-0391 – ident: e_1_3_3_17_2 doi: 10.1101/gad.269522.115 – ident: e_1_3_3_33_2 doi: 10.1371/journal.pone.0017911 – ident: e_1_3_3_43_2 doi: 10.1093/emboj/cdg542 – ident: e_1_3_3_50_2 doi: 10.1074/jbc.M204733200 – ident: e_1_3_3_16_2 doi: 10.1101/gad.191163.112 – reference: 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 – reference: 20601954 - Nat Genet. 2010 Aug;42(8):665-7 – reference: 21927022 - Oncogene. 2012 May 3;31(18):2283-97 – reference: 25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51 – reference: 21979956 - J Biol Chem. 2011 Dec 2;286(48):41425-33 – reference: 21215703 - Cancer Cell. 2011 Jan 18;19(1):86-100 – reference: 22508723 - Genes Dev. 2012 Apr 15;26(8):751-5 – reference: 21383005 - Mol Cancer Res. 2011 Apr;9(4):418-29 – reference: 22966359 - Oncol Lett. 2010 Jul;1(4):657-662 – reference: 20601953 - Nat Genet. 2010 Aug;42(8):722-6 – reference: 12379645 - J Biol Chem. 2002 Dec 13;277(50):48403-9 – reference: 21445301 - PLoS One. 2011 Mar 21;6(3):e17911 – reference: 12435631 - Genes Dev. 2002 Nov 15;16(22):2893-905 – reference: 22391448 - Genes Dev. 2012 Mar 1;26(5):439-44 – reference: 22522925 - Nature. 2012 Apr 18;486(7403):346-52 – reference: 26271144 - Biomed Pharmacother. 2015 Oct;75:218-25 – reference: 26683709 - Oncotarget. 2016 Jan 26;7(4):4584-97 – reference: 22393369 - PLoS One. 2012;7(2):e31761 – reference: 22237106 - Nature. 2012 Jan 11;481(7380):157-63 – reference: 18432192 - Nature. 2008 Jun 5;453(7196):807-11 – reference: 17482131 - Cancer Cell. 2007 May;11(5):407-20 – reference: 12052835 - J Biol Chem. 2002 Aug 16;277(33):29936-44 – reference: 14532106 - EMBO J. 2003 Oct 15;22(20):5323-35 – reference: 25043748 - Mol Carcinog. 2015 Oct;54(10 ):1172-80 – reference: 10963602 - Nature. 2000 Aug 17;406(6797):747-52 – reference: 23529930 - Blood. 2013 May 30;121(22):4512-20 – reference: 15780936 - Mol Cell. 2005 Mar 18;17(6):793-803 – reference: 19340297 - PLoS One. 2009;4(4):e5011 – reference: 23223005 - Nat Med. 2013 Jan;19(1):50-6 – reference: 24055345 - Mol Cell. 2013 Oct 24;52(2):193-205 – reference: 22237151 - Nat Med. 2012 Feb 06;18(2):298-301 – reference: 22766277 - Mol Oncol. 2012 Oct;6(5):494-506 – reference: 18176935 - Mol Carcinog. 2008 Sep;47(9):701-6 – reference: 21884980 - Mol Cell. 2011 Sep 2;43(5):798-810 – reference: 18806826 - Oncogene. 2008 Dec 11;27(58):7274-84 – reference: 23684459 - Cancer Cell. 2013 Jun 10;23 (6):839-52 – reference: 23239736 - Science. 2012 Dec 14;338(6113):1465-9 – reference: 23000897 - Nature. 2012 Oct 4;490(7418):61-70 – reference: 21225456 - Breast Cancer Res Treat. 2011 Apr;126(3):803-10 – reference: 22505648 - Cancer Res. 2012 Jun 15;72 (12 ):3091-104 – reference: 26637281 - Genes Dev. 2015 Dec 15;29(24):2547-62 – reference: 19097132 - J Cell Biochem. 2009 Feb 1;106(2):247-56 – reference: 19813088 - Breast Cancer Res Treat. 2010 Jul;122(2):337-46 – reference: 26512116 - Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23 – reference: 17024177 - EMBO J. 2006 Oct 18;25(20):4784-94 – reference: 21507930 - Cancer Res. 2011 Jun 15;71(12 ):4292-302 – reference: 26517694 - J Clin Invest. 2015 Oct 26;125(12 ):4375-90 – reference: 19411834 - Cell Cycle. 2009 Jun 15;8(12 ):1966-7 – reference: 17437993 - Genes Dev. 2007 May 1;21(9):1050-63 – reference: 9235919 - J Biol Chem. 1997 Aug 1;272(31):19253-60 – reference: 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 – reference: 21558518 - JAMA. 2011 May 11;305(18):1873-81 – reference: 26766588 - Cancer Cell. 2016 Jan 11;29(1):17-31 – reference: 12829800 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 – reference: 11641274 - Genes Dev. 2001 Oct 15;15(20):2675-86 – reference: 24516139 - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103 – reference: 24156323 - Future Oncol. 2013 Nov;9(11):1623-36 – reference: 23051747 - Nature. 2012 Dec 6;492(7427):108-12 – reference: 23768511 - Adv Cancer Res. 2013;118:97-398 – reference: 17898080 - Mol Biol Cell. 2007 Dec;18(12 ):4691-7 |
SSID | ssj0009580 |
Score | 2.4723017 |
Snippet | Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however,... The plasticity of Polycomb repressive complex 2 (PRC2) in the context of tumorigenesis has remained a subject of contention. Here we demonstrate that the... |
SourceID | pubmedcentral proquest pubmed crossref jstor |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | E3735 |
SubjectTerms | Biological Sciences Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - physiopathology Cell Line, Tumor Cell Proliferation Enhancer of Zeste Homolog 2 Protein - genetics Enhancer of Zeste Homolog 2 Protein - metabolism Humans Hypoxia-Inducible Factor 1, alpha Subunit - genetics Hypoxia-Inducible Factor 1, alpha Subunit - metabolism PNAS Plus Polycomb Repressive Complex 2 - genetics Polycomb Repressive Complex 2 - metabolism |
Title | HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer |
URI | https://www.jstor.org/stable/26470665 https://www.ncbi.nlm.nih.gov/pubmed/27303043 https://www.proquest.com/docview/1800702831 https://pubmed.ncbi.nlm.nih.gov/PMC4932959 |
Volume | 113 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbKuOEGMWBQ_mQkJg1V2ZLYsZvLUnXqEKsqtKHdVYljbxEjndoU2B6DN-FFeCaOf_LTsUnATVQldiLl-3rO8cl3jhF6QwLFJI18jwrBPRoExEs4ZV5AlZ-CQ8uY6c5_OGHjY_r-JDrpdH60VEurMt0VVzfWlfwPqnAOcNVVsv-AbH1TOAG_AV84AsJw_CuMxwf7B972cLT9LjBNMWx61Wxtu4DYctlLetpvuXTf8lte2gSHKY9KFkk2_24wqiWGV2e6Uer04zDUw1ItWC-1Lkw4Da-LYqe111tWGoNJlVQcNCUqzm4se15vOhm0kt-6SbRJu16ef81rv-A0QdNVctn7IJ1HNVGqtUeHeSMalovTZF58turwT3nhpEAufREwLbNy5eDSmlyIWDxG7aahtU22BaqOfGHbxI4Itw1O_jD-YK30jsVFstQ5s9DnsbtNiwoXXwwXIGjT34RJ4wVrbWJ16Q66G8LSw4hFx-1Gzn2_ahHFyd61p-ne0m7-WqBjta43rWKui3Fb0c3RA3TfLUvwwHJsE3Vk8RBtVgDiHded_O0jpAzpfv3EDeFwTTic4IZw2BIO5wUGhuAW4bAmHJ4rrAm3p-mmB1m6YUu3x-h4f3Q0HHtusw5PQAxYekJypfoKXoSSIQsFoBoTP5aEsb7IYhUTEvmZZLoYnMcy6ftpyoSigqURF3FKttBGMS_kU4SFH0kVRikFB0NDxWIRMpEGWRapWFHOu2i3erMz4TrZ6w1VzmdGUcHJTKMya1Dpop16woVt4nL70C0DVT0OFgxcf57sotcVdjOwwPqzWlLI-Qom93XPLAjTgy56YrFsZjsydBFfQ7keoLu7r18p8jPT5Z3CyiqO4me33vM5utf8oV6gjXKxki8hQi7TV4ayvwFdI7mN |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIFI-%CE%B1+activation+underlies+a+functional+switch+in+the+paradoxical+role+of+Ezh2%2FPRC2+in+breast+cancer&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Mahara%2C+Sylvia&rft.au=Lee%2C+Puay+Leng&rft.au=Feng%2C+Min&rft.au=Tergaonkar%2C+Vinay&rft.date=2016-06-28&rft.eissn=1091-6490&rft.volume=113&rft.issue=26&rft.spage=E3735&rft_id=info:doi/10.1073%2Fpnas.1602079113&rft_id=info%3Apmid%2F27303043&rft.externalDocID=27303043 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8424&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8424&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8424&client=summon |